Proton Intelligence, a company developing the first-ever Continuous Potassium Monitoring (CKM) platform, announced the closing of its $6.95 million Seed Financing round joined by SOSV, We Venture Capital, Tenmile, LongeVC, 15th Rock, Exor, and Trampoline Venture Partners.
The CKM platform was designed to transform the management of cardio-kidney-metabolic diseases by providing clinicians and patients with crucial data about potassium levels on demand. Potassium is both the most important biomarker in cardiac-kidney-metabolic diseases and the hardest to measure. And dangerous fluctuations in potassium levels—whether too high or too low—lead to cardiac arrhythmias and sudden cardiac death.
This inability to provide timely potassium levels to patients and providers is a major barrier to getting patients on the correct life-saving therapies. And about 33% of people with chronic kidney disease (CKD) or heart failure (HF) unnecessarily stop life-saving treatment after a high potassium event, which results in a nearly 40% increase in 6-month mortality. Proton’s CKM technology aims to provide providers and patients with accurate, remote, continuous potassium levels, allowing precise treatment of patients suffering from kidney disease or heart failure.
The company initiated clinical studies assessing the performance of CKM in people living with severely impaired kidney function, such as the underserved population living with end-stage renal disease (ESRD) or chronic kidney disease (CKD). And according to the United States Renal Data System (USRDS), 14% of US adults have CKD and account >25% of Medicare spend. Patients with ESRD account for 7% of US Medicare expenditure annually.
KEY QUOTES:
“We are proud to be the first institutional investor in Proton Intelligence. The team’s exceptional focus and relentless execution inspire confidence, and we are excited to continue to support them as they move into clinical validation.”
- Mohan S. Iyer, General Partner at SOSV
“We Venture Capital have been impressed by this true breakthrough in electrolyte sensing capability, which will fulfil a critical gap in the current care continuum for many patients at risk from dyskalemia. We look forward to working with the Proton Intelligence team on the next phase of their journey.”
- Dr. Louise Warme, Head of We Venture Capital
“The ability to continuously monitor potassium will enable better data-driven decision-making for patients with late-stage chronic kidney disease or on dialysis, not only improving outcomes for these patients but saving health systems considerable costs.”
- Dr. Steve Burnell, Managing Director at Tenmile
“This fundraising milestone represents a major leap forward for us. We are immensely grateful for the trust and support of our investors, who share our vision of revolutionizing cardio-kidney-metabolic care. Their belief in our mission sees us funded through a number of clinical feasibility trials ahead of a pivotal study planned for 2026 and get closer to making CKM a reality for millions of patients.”
- Dr. Sahan Ranamukhaarachchi, Founder and CEO of Proton Intelligence
